Shanghai Fudan Zhangjiang Bio Pharmaceutical Co (DE:FDY) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. reports an increase in revenue to RMB 408,124,000 and a rise in profit before income tax to RMB 72,187,000 for the first half of 2024, demonstrating sustained growth compared to previous years. The company’s earnings per share have also experienced a positive surge to RMB 0.0680, reflecting a robust financial performance.
For further insights into DE:FDY stock, check out TipRanks’ Stock Analysis page.
